A randomized and open-label dose-finding, phase 2, efficacy, safety and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO TM versus pegfilgrastim (NeulastaR) in stage II, III, or IV breast cancer patients at high risk of chemotherapy-induced neutropenia (CIN)

Trial Profile

A randomized and open-label dose-finding, phase 2, efficacy, safety and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO TM versus pegfilgrastim (NeulastaR) in stage II, III, or IV breast cancer patients at high risk of chemotherapy-induced neutropenia (CIN)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Pegfilgrastim ANF (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top